Last updated: August 3, 2026
Perampanel, marketed by Eisai as Fycompa, is a branded small-molecule antiseizure medicine with global sales concentrated in epilepsy maintenance therapy. Its commercial position is durable because of broad regulatory labeling, once-daily oral dosing, and adjunctive use across seizure types. Its main constraint is generic exposure: the core composition patent has expired in the United States, while later formulation, crystalline-form, and method-of-use patents may delay or narrow generic competition rather than preserve full product exclusivity.
What is perampanel and how is it positioned commercially?
Perampanel is a selective, noncompetitive antagonist of AMPA-type glutamate receptors. It is approved for focal-onset seizures and primary generalized tonic-clonic seizures, either as monotherapy or adjunctive therapy depending on jurisdiction and label.
| Product attribute |
Perampanel |
| Brand |
Fycompa |
| Active ingredient |
Perampanel |
| Developer and originator |
Eisai Co., Ltd. |
| Drug class |
AMPA receptor antagonist |
| Initial U.S. approval |
October 22, 2012 |
| U.S. dosage forms |
Tablets and oral suspension |
| Common strengths |
2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg |
| Administration |
Once daily |
| Primary markets |
United States, Japan, Europe, Asia-Pacific |
| Regulatory pathway |
New drug application for a small molecule |
| Biosimilar exposure |
None; biologic substitution rules do not apply |
The product competes with levetiracetam, brivaracetam, lacosamide, lamotrigine, and other antiseizure medicines. Perampanel’s once-daily dosing and distinct mechanism support use in patients whose seizures remain uncontrolled on other therapies. Its limitations include dizziness, somnolence, irritability, aggression, and other psychiatric or behavioral adverse events identified in the U.S. prescribing information.[1]
When did Fycompa receive FDA approval and what does the label cover?
The FDA approved Fycompa in 2012 as adjunctive therapy for partial-onset seizures in patients aged 12 years and older. The agency later expanded the label to include primary generalized tonic-clonic seizures and younger pediatric patients.
Key U.S. milestones include:
| Date |
FDA milestone |
| October 2012 |
Initial approval for adjunctive treatment of partial-onset seizures |
| 2014 |
Approval for primary generalized tonic-clonic seizures |
| 2017 |
Approval of oral suspension |
| 2018 |
Expansion to pediatric patients aged 4 years and older |
| 2021-2022 |
Label and exclusivity period affected by pediatric development incentives |
The oral suspension broadens use in pediatric patients and patients who cannot swallow tablets. It also creates a separate formulation and regulatory pathway for generic manufacturers, although an approved tablet generic may still pressure overall brand demand.
How large are perampanel sales and what is the financial trajectory?
Eisai does not generally report Fycompa as a separately listed public-company segment with the same detail used for its largest oncology products. Public annual reports indicate that Fycompa has generated a relatively stable annual revenue base in the range of approximately ¥40 billion to ¥50 billion in recent years, rather than the rapid growth associated with a newly launched specialty medicine.[2]
Perampanel revenue profile
| Period |
Commercial interpretation |
| 2012-2015 |
Launch and geographic expansion |
| 2016-2019 |
Growth from broader seizure indications and international uptake |
| 2020-2022 |
Mature branded product with generally stable demand |
| 2023 onward |
Increasing generic and patent-related pressure, varying by market |
The product’s financial value is supported by chronic treatment duration. Epilepsy patients often remain on therapy for years, creating recurring prescription volume. Revenue is less dependent on acute hospital use than many specialty medicines.
The principal economic risks are:
- Generic price erosion after market entry.
- Substitution within the antiseizure category.
- Payer preference for lower-cost levetiracetam and other established agents.
- Safety concerns involving psychiatric and behavioral effects.
- Reduced commercial leverage as later-line use becomes more common.
Perampanel is commercially important to Eisai, but it is not comparable in revenue scale to the company’s oncology franchise, including lenvatinib and associated combination products.
What patents protect perampanel and Fycompa?
Perampanel’s U.S. patent estate has included several categories:
- Core chemical composition patents.
- Crystalline-form and solid-state patents.
- Pharmaceutical composition patents.
- Manufacturing and purification patents.
- Method-of-use patents covering seizure treatment.
- Pediatric and formulation-related exclusivity.
The original composition protection is no longer the main barrier to generic entry. Later patents may remain relevant, but they generally provide narrower protection than the original compound patent.
Core patent and regulatory exclusivity timeline
| Protection type |
Commercial relevance |
| Original compound patent |
Expired or reached its effective U.S. term around the early 2020s |
| Pediatric exclusivity |
Added six months to eligible patent or exclusivity periods |
| U.S. method-of-use patents |
May extend into the late 2020s or early 2030s, depending on patent and claim scope |
| Formulation patents |
Potentially relevant to oral suspension and specific dosage forms |
| Data exclusivity |
Completed for the original U.S. approval; it does not replace patent protection |
| European supplementary protection |
Country-specific and dependent on the underlying patent and regulatory history |
The precise generic-entry date depends on which patents remain listed in the FDA Orange Book, whether generic applicants filed Paragraph IV certifications, the scope of any carve-outs, and whether litigation produced a stay or settlement.[3]
What is the Orange Book status of Fycompa?
Fycompa is an FDA-approved small-molecule product and has been subject to Orange Book patent listing. The relevant listed patents can cover the active ingredient, approved formulations, or approved methods of use.
An Orange Book listing does not mean that all listed patents block every generic product. A generic applicant can:
- Certify that a patent has expired.
- File a Paragraph III certification and wait for expiration.
- File a Paragraph IV certification alleging invalidity, unenforceability, or non-infringement.
- Use a section viii statement to omit a patented method of use.
- Seek approval for a dosage form or indication that avoids the relevant claim.
For perampanel, the commercial effect of Orange Book patents is therefore claim-specific. A generic tablet could enter while a separate oral-suspension patent remains contested, or a generic could omit a patented indication through labeling restrictions.
When does perampanel lose exclusivity in the United States?
Perampanel has already lost the protection provided by its original compound patent. The more important question is whether later patents delay commercial generic substitution.
A practical U.S. exclusivity assessment is:
| Protection layer |
Status |
| New chemical entity exclusivity |
Expired |
| Original composition patent |
Expired or no longer the primary barrier |
| Pediatric exclusivity |
Completed |
| Formulation protection |
Potentially relevant to specific products |
| Method-of-use protection |
Potentially relevant to labeled indications |
| Generic tablet risk |
High |
| Generic oral-suspension risk |
Dependent on formulation and labeling patents |
Generic launch risk is therefore asymmetric. Tablet competition is likely to develop before all formulation or method-of-use protections disappear. Brand retention may be stronger in pediatric patients and in patients using the oral suspension, but that protection is commercial rather than absolute.
Have generic manufacturers challenged Fycompa patents?
Generic manufacturers seeking FDA approval can challenge listed Fycompa patents through Paragraph IV certifications. Public commercial risk analysis should distinguish between:
- An ANDA filing.
- A Paragraph IV notice letter.
- Patent litigation under the Hatch-Waxman Act.
- FDA approval.
- Actual commercial launch.
These events are not interchangeable. A Paragraph IV filing can trigger litigation and a 30-month FDA approval stay, but it does not guarantee that the generic will launch before patent expiration.
The principal generic strategies are likely to involve:
- Perampanel tablets across the 2 mg to 12 mg strength range.
- A label that omits protected indications or uses.
- Separate development of oral suspension.
- Challenges to crystalline-form or formulation claims.
- At-risk launch after a favorable court ruling or an invalidity determination.
A complete current list of challengers and case outcomes requires live review of FDA Orange Book entries, ANDA litigation records, and district-court dockets. The commercial conclusion remains clear: perampanel is exposed to generic competition because the core molecule is mature and no biologic manufacturing barrier applies.
What formulation patents protect perampanel?
Formulation protection is commercially relevant because Fycompa is available as both tablets and oral suspension.
Potential claim categories include:
- Specific crystalline forms of perampanel.
- Particle-size distributions.
- Tablet excipient combinations.
- Suspension vehicles and stabilizers.
- Dose uniformity and physical stability.
- Manufacturing processes that improve purity or yield.
A formulation patent usually does not prevent every generic version of the active ingredient. Its value depends on whether the generic can use a different formulation without losing bioequivalence, stability, patient usability, or FDA approval.
The oral suspension may have greater formulation complexity than standard tablets. That can raise development costs and slow substitution, but it does not create the same barrier as a complex injectable or biologic product.
What method-of-use patents cover perampanel?
Method-of-use patents can cover treatment of particular seizure types, patient populations, dosing regimens, or combinations with other antiseizure medicines.
These patents can affect the approved label through a section viii carve-out. A generic manufacturer may omit a patented use while retaining approval for unprotected uses. This creates a partial-competition scenario:
- Generic tablets enter for non-patented indications.
- Fycompa retains the patented indication on its label.
- Pharmacies and payers may still substitute the generic broadly.
- Enforcement depends on actual prescribing, promotion, and induced-infringement evidence.
Method-of-use patents are therefore weaker commercial barriers than a broad composition patent. Their value is greatest where the protected use represents a substantial share of prescriptions and where substitution controls are effective.
What is the risk of biosimilars for perampanel?
There is no biosimilar risk for perampanel. Perampanel is a chemically synthesized small molecule regulated through the ANDA pathway, not a biologic regulated under the Biologics Price Competition and Innovation Act.
The competitive risk is conventional generic competition. Generic manufacturers generally need to demonstrate pharmaceutical equivalence and bioequivalence rather than reproduce a biologic manufacturing process. This reduces technical barriers and can accelerate price competition after patent resolution.
How does perampanel compare with competing antiseizure drugs?
| Drug |
Brand originator |
Mechanism or profile |
Commercial position |
| Perampanel |
Eisai |
AMPA antagonist; once daily |
Differentiated mechanism, mature brand |
| Levetiracetam |
UCB |
SV2A ligand |
Large generic base and low cost |
| Brivaracetam |
UCB |
Higher-affinity SV2A ligand |
Branded and specialty positioning |
| Lacosamide |
UCB |
Sodium-channel modulation |
Broad use and generic competition |
| Lamotrigine |
GSK and others |
Sodium-channel modulation |
Long-established, low-cost generic |
| Cenobamate |
SK Biopharmaceuticals/Angelini |
Multimodal antiseizure activity |
Newer branded growth product |
Perampanel’s strongest commercial differentiator is its mechanism combined with once-daily dosing. Its weakest position is cost after generic entry. Physicians may retain it for patients who respond well, but payers can favor generic alternatives for new starts and routine maintenance.
What licensing deals and manufacturing barriers affect perampanel?
Eisai developed and commercializes Fycompa globally. The product does not depend on a high-complexity biologic manufacturing platform, cold-chain distribution, or device-specific delivery system.
The key manufacturing barriers are chemical rather than biological:
- Control of impurities and residual solvents.
- Reproducible solid-state form.
- Tablet dissolution and content uniformity.
- Oral-suspension stability.
- Scale-up and process validation.
- Bioequivalence across multiple strengths.
These issues can delay individual generic applications, but they are unlikely to preserve premium pricing once several approved suppliers enter the market.
No major public licensing transaction is required to explain the product’s market position. Its economics are principally determined by Eisai’s retained commercialization, regulatory status, patent litigation, and generic entry timing.
What patent litigation affects Fycompa?
The relevant litigation framework is Hatch-Waxman litigation between Eisai and ANDA applicants. The decisive issues are likely to include:
- Whether listed patents are valid.
- Whether generic products infringe crystalline-form or formulation claims.
- Whether method-of-use claims support a full-label challenge.
- Whether a 30-month stay applies.
- Whether settlement terms include a licensed entry date.
- Whether an authorized generic is introduced.
A settlement can convert litigation uncertainty into a defined generic-entry date. If the settlement allows early entry, the revenue decline can begin before the final patent expiry. If no settlement occurs, the first generic may launch after a court ruling or after patent expiration.
What generic launch scenarios exist for perampanel?
Early negotiated entry
Eisai and one or more generic companies agree to an entry date before the latest asserted patent expires. This often produces a rapid decline in branded volume once the first generic launches.
At-risk launch
A generic launches before all litigation is resolved. This can create significant price erosion and later damages exposure if the patent holder prevails.
Delayed tablet competition
Generic tablets enter after the core and method-of-use issues are resolved, while oral suspension remains protected or commercially difficult to replicate.
Multi-generic erosion
Several suppliers enter within a short period. This is the most severe scenario for brand revenue because pharmacy substitution and payer contracting intensify.
For a mature oral small molecule, the multi-generic scenario is the main long-term risk. Eisai may retain revenue through residual branded prescribing, supply contracts, and markets where generic approval or substitution is slower.
What is the geographic coverage of perampanel protection?
Patent and exclusivity outcomes differ by jurisdiction.
- United States: FDA Orange Book patents and Hatch-Waxman litigation control generic timing.
- European Union: national validation, national litigation, and country-specific generic approval affect launch.
- Japan: Japanese patent rights and PMDA approval determine competition.
- China: patent linkage and national regulatory procedures influence timing.
- Emerging markets: local patent terms, compulsory licensing rules, and tender procurement can accelerate price erosion.
A U.S. patent expiry does not establish global freedom to launch. Conversely, generic competition in one jurisdiction can reduce reference pricing and weaken brand economics elsewhere.
How strong is the perampanel patent estate?
Perampanel’s patent estate is moderate, not strong.
| Factor |
Assessment |
| Core molecule protection |
Weak because the principal term has expired |
| Formulation protection |
Moderate for narrowly defined products |
| Method-of-use patents |
Moderate but vulnerable to label carve-outs |
| Manufacturing patents |
Limited blocking power unless process is essential |
| Biologic-style complexity |
Absent |
| Generic substitution risk |
High |
| Long-term brand protection |
Low to moderate |
The estate can delay or segment generic competition. It is unlikely to support long-term broad exclusivity comparable to a product protected by an unexpired composition patent, a complex delivery system, or biologic manufacturing know-how.
Key Takeaways
- Perampanel is Eisai’s mature branded antiseizure medicine marketed as Fycompa.
- U.S. FDA approval began in 2012, with later expansions for generalized seizures, pediatric patients, and oral suspension.
- Recent annual sales have generally been in the approximate ¥40 billion to ¥50 billion range based on Eisai reporting.
- The original compound patent is no longer the principal U.S. exclusivity barrier.
- Later formulation, crystalline-form, manufacturing, and method-of-use patents may affect specific generic products.
- Generic competition is the central financial risk; biosimilar risk does not apply.
- Tablet substitution is likely to precede or exceed oral-suspension competition.
- Perampanel has a moderate patent estate but limited ability to sustain broad premium pricing after multi-generic entry.
- Revenue should be modeled as mature and recurring before generic entry, followed by potentially steep erosion after the first interchangeable or therapeutically substitutable generic launches.
FAQs
Is perampanel still under patent protection?
Some later patents may protect particular formulations, crystalline forms, manufacturing processes, or methods of use. The original compound protection is no longer the primary barrier.
Is Fycompa a biologic drug?
No. Fycompa contains the chemically synthesized small molecule perampanel and competes through the generic-drug pathway.
Will generic perampanel be interchangeable with Fycompa?
Interchangeability depends on the dosage form, FDA approval, state substitution law, and pharmacy benefit design. Tablets and oral suspension should be assessed separately.
Does a Paragraph IV filing mean a generic perampanel launch is imminent?
No. A Paragraph IV certification can trigger patent litigation and an FDA approval stay. Launch timing depends on litigation, settlement, patent expiry, and regulatory approval.
Which product is the main commercial threat to perampanel?
Low-cost generic levetiracetam and other established generic antiseizure drugs create the largest economic pressure. Branded products such as brivaracetam and cenobamate compete for newer or refractory patients.
References
- U.S. Food and Drug Administration. (2023). Fycompa (perampanel) prescribing information. FDA.
- Eisai Co., Ltd. (2024). Integrated report 2024 and fiscal year financial results. Eisai Co., Ltd.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
